Gilde Healthcare is a specialized healthcare investor with two primary fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund targets innovative healthtech and therapeutics companies in Europe and North America, while the Private Equity fund focuses on profitable European lower mid-market healthcare providers, suppliers, and service providers. Their overarching investment philosophy is to support businesses that enable better care at lower cost.
50% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (40% of deals). Average disclosed round size is $67.0M (across 19 rounds with reported amounts).
Portfolio
20
Fund Size
$2.6B
Top Stage
Series B
Last 12 Mo
7
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
20 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Endovascular Engineering, Inc. | Series C | $80M | Apr 2026 |
 Big Health | Unknown | $23.7M | Feb 2026 |
| PProVerum | Series B | $68.6M | Aug 2025 |
 ProVerum Limited | Series B | $80M | Aug 2025 |
 GT Medical Technologies, Inc. | Series D | $53M | Jul 2025 |
 SpliceBio | Series B | $135M | Jun 2025 |
 SpyGlass Pharma | Series D | $75M | Jun 2025 |
| SShoulder Innovations | Series E | $40M | Mar 2025 |
| GT Medical Technologies, Inc. | Series D | $37M | Jan 2025 |
 Noema Pharma | Series B | — | Dec 2024 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Purespring Therapeutics | Series B | $105M | Oct 2024 |
 Karius | Series D | $100M | May 2024 |
 Tagworks Pharmaceuticals | Series A | $65M | Jun 2023 |
| GT Medical Technologies, Inc. | Series C | $45M | Mar 2023 |
| SpliceBio | Series A | $50M | Feb 2022 |
| Noema Pharma | Series A | $59M | Dec 2020 |
 Withings | Series B | $60M | Jul 2020 |
| Big Health | Series B | $39M | Jun 2020 |
| CCalypso Biotech | Series A | $22.6M | Feb 2019 |
Top Co-Investors
Ysios Capital4 shared
OrbiMed3 shared
Lightstone Ventures3 shared
NEA (New Enterprise Associates)3 shared
Novartis Venture Fund3 shared
Sofinnova Partners3 shared
Atlantic Bridge2 shared
Enterprise Ireland2 shared
Evidity Health Capital2 shared
Accelmed Partners2 shared
RA Capital Management2 shared
Forbion2 shared
UCB2 shared
Asabys2 shared
EQT Life Sciences2 shared
Polaris Venture Partners2 shared
Invus2 shared
Idinvest1 shared
Bpifrance1 shared
Adelie Capital1 shared
Last updated: 15 April 2026